Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

Ants show the potential to become a fast, efficient, inexpensive, and non-invasive tool for the detection of human tumors

Researchers demonstrated the use of ants as olfactory bio-detectors of human tumors.

31 Jan 2023

Study elucidates the potential role of STRO-001 in B-cell non-Hodgkin lymphoma

A new research paper was published in Oncotarget's Volume 14 on January 12, 2023, entitled, "Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001."

18 Jan 2023

Study uncovers a new role for Slit2 signaling in stimulating Ewing sarcoma growth

A new research paper was published in Genes & Cancer on December 14, 2022, entitled, "Slit2 signaling stimulates Ewing sarcoma growth."

13 Jan 2023

New cooling strategy could prevent the growth of glioblastoma

Cooling brain tumor cells to stop them from dividing without killing healthy cells extended the survival of glioblastoma (GBM) animal models dramatically in a study led by a UT Southwestern resident.

12 Jan 2023

Simple method increases the efficacy of T cell therapy by cytokine conjugation

The recent years have seen a wave of adoptive cell therapies (ACTs), a type of immunotherapy in which T cells (T cell transfer therapy) and other immune cells are obtained from patients, activated and multiplied outside the body, and infused in larger numbers back into the blood circulation to help fight cancers.

11 Jan 2023

CAR T-cell therapy in colorectal cancer

Researchers assessed the efficacy of CAR T-cells in the immunotherapy of colorectal cancer.

21 Nov 2022

Pt(IV)-conjugated drug-delivery system shows efficacy in glioblastoma therapy

A recent study demonstrated a novel method for delivering anti-cancer drugs, conjugated to modified cell-penetrating peptides across the blood-brain barrier, in mice to treat glioblastoma.

18 Nov 2022

First pig-to-human cardiac transplant alters heart's electrical signals

A recent study to be presented at the American Heart Association (AHA) Scientific Sessions 2022* revealed unexpected changes in the electrical conduction system of the first genetically-modified porcine-to-human heart xenotransplant.

1 Nov 2022

Piceatannol and mTOR inhibitor combination proves be an attractive therapeutic strategy for gastric cancer

This study is led by Dr. Longtao Huangfu, and Dr. Xiaoyang Wang (Peking University Cancer Hospital & Institute). A diet of fresh fruits and vegetables may reduce the prevalence of cancers, including GC (Eusebi et al., 2020; Liu et al., 2021).

28 Oct 2022

Largest academic collaboration aims to transform the treatment for pediatric cancers

The Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute and St. Jude Children's Research Hospital today announced the largest academic collaboration of its kind to transform and accelerate the identification of vulnerabilities in pediatric cancers and translate them into better treatments.

13 Oct 2022

Signal transduction via the EGFR pathway likely to be involved in lenvatinib resistance

The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become resistant to lenvatinib remain poorly understood. In this study, we demonstrated, for the first time, that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells.

14 Sep 2022

New biomimetic formulation developed to tackle glioblastoma multiforme

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore urgently needed.

22 Jul 2022

Damon Runyon Cancer Research Foundation names five new Damon Runyon Clinical Investigators

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

6 Jul 2022

UH experts in cloning and stem cell science take the first step toward unraveling cystic fibrosis

Two nationally recognized experts in cloning and stem cell science from the University of Houston are taking the first step toward limiting the consequences of chronic inflammation in cystic fibrosis (CF) by identifying the source of this persistent and enigmatic inflammation in CF lungs.

24 May 2022

Anti-Müllerian hormone plays an active role in polycystic ovary syndrome

High levels of anti-Mullerian hormone (AMH) have traditionally been thought of as merely a passive byproduct of polycystic ovary syndrome (PCOS), but a new preclinical study by Weill Cornell Medicine researchers suggests that the hormone plays an active role in the disorder and may contribute to problems with ovulation and fertility.

10 Mar 2022

New, highly promising strategy to overcome a key cause of cancer deaths

A research team led by scientists at Albert Einstein College of Medicine has devised a novel and highly promising strategy for overcoming a key cause of cancer deaths: the ability of cancer cells to thrive in the face of chemotherapy drugs designed to destroy them.

7 Mar 2022

New approach for extensive screening of monoclonal antibody clones against multiple myeloma cells

Multiple myeloma (MM) is a largely incurable cancer of plasma cells with an extremely poor prognosis. However, investigators from Japan have recently found that a common component of amino acid transporters, CD98 heavy chain, represents an effective monoclonal antibody target in treating MM.

22 Feb 2022

New approach to CAR T-cell therapy for B-cell cancers triples the targeted antigens on cancer cells

Researchers at University Hospitals Seidman Cancer Center and Case Western Reserve University have developed a novel approach to chimeric antigen receptor (CAR) T-cell therapy for B-cell cancers that triples the targeted antigens on cancer cells – a "back up" approach that promises to greatly reduce the potential for antigen escape currently found in CAR T therapies that solely target CD19.

2 Feb 2022

UCLA study provides new insights into molecular 'crosstalk' in pancreas cancer cells

Research led by scientists at the Jonsson Comprehensive Cancer Center (JCCC) at UCLA provides new insights into molecular "crosstalk" in pancreas cancer cells, identifying vulnerabilities that could provide a target for therapeutic drugs already being studied in several cancers.

12 Jan 2022

MAPK4 may play a key role in triple-negative breast cancer

Scientific evidence supporting the involvement of the enzyme MAPK4 in cancer growth and resistance to certain therapies has been growing quickly.